A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.
about
Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipientsIssues in solid-organ transplantation in children: translational research from bench to bedside.Metabolic and cardiovascular complications in the liver transplant recipientTranscriptional regulators of claudins in epithelial tight junctionsTacrolimus (FK506)-induced severe and late encephalopathy in a renal transplant recipientCyclosporin-induced flushing in a renal transplant recipient resolving after substitution with tacrolimusMycophenolate mofetil enhances the negative effects of sirolimus and tacrolimus on rat kidney cell metabolismProphylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem.Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial dataTacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury.NaCl cotransporter abundance in urinary vesicles is increased by calcineurin inhibitors and predicts thiazide sensitivity.Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles.{beta}-Cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplantsQuantitation of allograft fibrosis and chronic allograft nephropathy.Face transplantation: on the verge of becoming clinical routine?Cardiac allograft vasculopathy: current knowledge and future direction.Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events.Recurrent and de novo diseases after renal transplantation.PharmGKB summary: cyclosporine and tacrolimus pathwaysImmunosuppression for lung transplantation.Calcineurin-inhibitors in renal transplantation. Too precious to be abandoned.The metabolic effects of cyclosporin and tacrolimus.Review of select transplant subpopulations at high risk of failure from standard immunosuppressive therapy.Reduction of severe gingival overgrowth in a kidney transplant patient by replacing cyclosporin A with tacrolimus.Immunologic considerations in composite tissue transplantation: overview.Current treatment practice in immunosuppression.Human islet cell transplantation--future prospects.Outcome of tacrolimus conversion therapy for renal allograft rejection: 5-year follow-upImmunosuppression without immunosuppression? How to be a tolerant individual in a dangerous world.Long-term results of pancreas transplantation under tacrolius immunosuppression.Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature.Tacrolimus for rescue of refractory renal allograft rejectionNew-onset diabetes after transplantation in tacrolimus-treated, living kidney transplantation: long-term impact and utility of the pre-transplant OGTT.Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.Molecular mechanisms of renal allograft fibrosis.Immunosuppressive Medications.Immunosuppressive therapy and post-transplantation diarrhea.Prophylaxis and treatment of gastrointestinal complications following transplantation.Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipientsImmunosuppression: practice and trends.
P2860
Q24245456-B7EBC3E4-FDC4-45C0-B7FC-66E02BE42F9CQ27023312-6DABAEB6-6CAA-4B11-A0D2-B615BCDC9F58Q28082243-B9881B23-A084-48F0-81BC-D7D983683B97Q28261649-BA8B26A4-0ADE-4DA1-B06B-CD00AF328260Q28374591-CFB9C1D5-F724-4901-A093-FF2114770977Q28378195-49949F38-2192-4BCC-9004-4503A25B5FA3Q28539334-25836EAE-ADDB-4FD8-8FC9-68EBE20C1450Q30583015-BFC04203-3CCA-4003-8239-830929910635Q31004418-DE59B7FF-E9DC-4C71-8C7B-2D4A1D8A69D6Q31617397-53A5BF86-B4FD-4FA2-8C90-9D757541B053Q33590418-969E338E-6D19-4408-A564-1DB731897E41Q33670571-F08869CE-2DBA-4D2F-BA0D-97035DDF09DEQ33738693-0B8A9E53-B7D7-4371-92FF-3BAE4A18F6D8Q33774364-FF70D9AF-95F4-4934-A048-438C0BE0B1CEQ33804489-A5241CD8-4D6F-4BDE-8C85-6A9FB0DC789AQ33860323-BB0C22AA-6B1B-40F8-B229-954C91FCD2E8Q33926957-622217EE-FEE4-43AF-ABF9-29CF56AE6EF3Q33931041-70D52C23-70CF-4472-8849-01F7607C4215Q33989902-E554ABB7-FA6E-42D1-9FAB-FE1D9063CA1BQ33996931-45FAD763-7B22-46AA-8C3A-33A0346B8D06Q34025909-C65E05AE-5361-42C8-9206-EFB68D11078AQ34045311-09280BE1-244B-462B-A843-DDE2F904D006Q34069142-3998C18A-AF8D-42BE-AAFC-9DB347B9527CQ34076610-276D46B0-C267-4E16-A9F0-2AB1AE066CABQ34126611-55BFD7C1-05E6-42AB-91BE-07E00EA7CAC7Q34181796-938BC420-BAB4-4F77-8428-12A5D0AAD871Q34184785-76E98DA9-5541-4EC9-8AF3-E217D8114584Q34275879-7279C013-45CE-430E-852D-6CF6709AE18EQ34294802-299C2ACD-7CA0-48F7-A0F3-C28DF4547673Q34302128-65A3A16D-4418-4CC6-BF4F-40EEED0DA9ADQ34308806-04BDD016-1CB4-4AB3-9F19-897176339080Q34318175-D763984C-6221-4365-A842-F42F0FAF91ECQ34368857-9CBE8152-1352-42AB-B6C3-EE06EB13D1CEQ34369032-59D5D845-0332-477C-A068-62ACF9C9380CQ34421501-D35DAC72-8017-4D3C-95EC-134EB5BBBE73Q34484801-7AEFD3FF-93C9-450D-AA42-3214FF869082Q34485488-309EF11A-DAE6-4D6D-B975-11966410FC89Q34485493-C8992DC1-0A40-43F8-93DA-C920DC639F31Q34497165-147F1605-C8DC-482F-B757-69167EE7D145Q34547444-1452272E-3DAB-4FC0-B7F8-8DCA9771A612
P2860
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
A comparison of tacrolimus (FK ...... Kidney Transplant Study Group.
@en
type
label
A comparison of tacrolimus (FK ...... Kidney Transplant Study Group.
@en
prefLabel
A comparison of tacrolimus (FK ...... Kidney Transplant Study Group.
@en
P2093
P1433
P1476
A comparison of tacrolimus (FK ...... Kidney Transplant Study Group.
@en
P2093
P304
P356
10.1097/00007890-199704150-00013
P577
1997-04-01T00:00:00Z